BeiGene, Celgene Ink Up-to-$1.393B Cancer Immunotherapy Deal – Genetic Engineering & Biotechnology News
|
BeiGene, Celgene Ink Up-to-$1.393B Cancer Immunotherapy Deal
Genetic Engineering & Biotechnology News Celgene will take a 5.9% stake in BeiGene in an up-to-$1.393 billion cancer immunotherapy deal that will catapult the U.S.-based biotech giant to a top position in programmed death protein-1 (PD-1) checkpoint inhibitors, the companies said today … |
